Comparative Pharmacology
Head-to-head clinical analysis: NUBAIN versus ORAMORPH SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUBAIN versus ORAMORPH SR.
NUBAIN vs ORAMORPH SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
None Documented
None Documented
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic